Mi az ára 9 Meters Biopharma, Inc. (NMTR)

9 Meters Biopharma, Inc. (NMTR) ára $0.0169

Mi a 9 Meters Biopharma, Inc. (NMTR piaci tőkésítése)

9 Meters Biopharma, Inc. piaci tőkésítése (NMTR) $66.40K

9 Meters Biopharma, Inc. (NMTR) Árfolyamtörténet

Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.

Év	Teljesítmény
2023	-98.82%
2022	-92.87%
2021	7.49%
2020	28.30%
2019	-72.54%
2018	-60.37%
2017	-60.70%
2016	0.00%

Év

Teljesítmény

2023

-98.82%

2022

-92.87%

2021

7.49%

2020

28.30%

2019

-72.54%

2018

-60.37%

2017

-60.70%

2016

0.00%

Vállalat	Részvényár	Változás 1év%	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$524.45	32.46%	US
Argenx SE ARGX.US	$863.27	33.51%	NL
Lonza Group AG LONN.SW	$744.96	8.94%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.08K	-6.68%	KR
UCB S.A. UCB.BR	$259.89	16.65%	BE

Vállalat

Részvényár

Változás 1év%

Ország